Presently, the highly selective BCL2 inhibitor venetoclax (ABT-199) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [18] and, in combination with decitabine or azacitidine or low-dose cytarabine, for AML patients older than 75 years or unfit for intensive induction chemotherapy. Here, BCL2 is linked to acute myeloid leukemia.